YESCARTA® (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous 免费海外网站加速器下载 immunotherapy indicated for the treatment of adult patients with relapsed or refractory large 美国网络加速器免费版 lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) 外网加速器永久免费版官网, primary mediastinal large B-cell lymphoma, high grade 免费外国网络加速器 lymphoma, and DLBCL arising from follicular lymphoma.

Limitation of Use: YESCARTA is not indicated for the treatment of patients with primary central nervous system lymphoma.
Read MoreRead Less

TECARTUS™ (brexucabtagene autoleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

This indication is approved under accelerated approval based on overall response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

MENU
Home Find an Authorized Treatment Center Access REMS
免费海外网站加速器下载 For Referring Physicians Kite Konnect Referral Prescribing Information & Medication Guide Prescribing Information & Medication Guide

This site is intended for US healthcare professionals.
For patients and other support inquiries, call 1-844-454-KITE.

免费外国网络加速器 Adverse Events Product Complaint

ysscloud加速器官网

中国空中Wi-Fi市场预期达百亿(2)_旅游周刊·航空_新京报电子报:2021-5-10 · 免费很难支撑起空中Wi-Fi的未来,商业化才是未来趋势。 国际上,虽然也有航空公司免费提供,但是大多航空公司都收取服务费。 各国航空公司空中Wi-Fi收费模式主要有按航段、流量、使用时间、设备数量和内容点播众及24小时共享模式收费,也有包年和包月的计费方式。

patient icon

Patient
Enrollment

Hospital Portal access, Cell Order completion, and leukapheresis scheduling

海外永久免费软件加速器

Reimbursement
Support

外国人在京创业可享“一站式”服务-千龙网·中国首都网:2021-7-22 · 据介绍,国际人才创新创业港是由朝阳区和法国、爱尔兰、瑞士、新加坡、澳大利亚、荷兰、芬兰等国使馆创新部门共同建设的国际项目加速平台,方便国际创业者来朝阳落地发展,为外国来华创新项目提供12个月免费入驻加速服务。

永久免费国际加速器

Logistics
Support

Connecting patients with independent foundations to help with transportation and housing

rep icon

Ongoing
Commitment

Cell Order tracking and continuous communication

To learn more about the information and support we offer healthcare professionals and patients, please call Kite Konnect at 1-844-454-KITE.

ysscloud加速器官网

Begin the therapy process for your patient in just two steps:

human icon

外国人在京创业可享“一站式”服务-千龙网·中国首都网:2021-7-22 · 据介绍,国际人才创新创业港是由朝阳区和法国、爱尔兰、瑞士、新加坡、澳大利亚、荷兰、芬兰等国使馆创新部门共同建设的国际项目加速平台,方便国际创业者来朝阳落地发展,为外国来华创新项目提供12个月免费入驻加速服务。

Enroll Your Patient

IV drip icon

Once a patient is enrolled in the Kite Konnect Hospital Portal, you can initiate leukapheresis using the Apheresis Collection Application System (ACAS).

Initiate Leukapheresis

外网加速器永久免费版官网

Look for an Authorized Treatment Center located near your patient, or their caregiver, to take the first step toward therapy enrollment.

Locate an Authorized Treatment Center

United States icon

美国网络加速器免费版

Access the YESCARTA® and TECARTUS Risk Evaluation and Mitigation Strategy Program, or request access to training.

Access REMS Training

ysscloud加速器官网

ysscloud加速器官网

  • Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving YESCARTA®. Do not administer YESCARTA to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.
  • Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving YESCARTA, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with YESCARTA. Provide supportive care and/or corticosteroids as needed.
  • YESCARTA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the YESCARTA REMS.

CYTOKINE RELEASE SYNDROME

(CRS) occurred in 94% of patients, with 13% ≥ Grade 3. Among patients who died after receiving YESCARTA, 4 had ongoing CRS at death. The median time to onset was 2 days (range: 1-12 days) and median duration was 7 days (range: 2-58 days). Key manifestations include fever (78%), hypotension (41%), tachycardia (28%), hypoxia (22%), and chills (20%). Serious events that may be associated with CRS include cardiac arrhythmias (including atrial fibrillation and ventricular tachycardia), cardiac arrest, cardiac failure, renal insufficiency, capillary leak syndrome, hypotension, hypoxia, and hemophagocytic lymphohistiocytosis/macrophage activation syndrome. Ensure that 2 doses of tocilizumab are available prior to YESCARTA infusion. Following infusion, monitor patients for signs and symptoms of CRS at least daily for 7 days at the certified healthcare facility, and for 4 weeks thereafter. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time. At the first sign of CRS, institute treatment with supportive care, tocilizumab or tocilizumab and corticosteroids as indicated.



NEUROLOGIC TOXICITIES

occurred in 87% of patients, 98% of which occurred within the first 8 weeks with a median time to onset of 4 days (range: 1-43 days) and a median duration of 17 days. Grade ≥3 occurred in 31% of patients. The most common neurologic toxicities included encephalopathy (57%), headache (44%), tremor (31%), dizziness (21%), aphasia (18%), delirium (17%), insomnia (9%), and anxiety (9%). Prolonged encephalopathy lasting up to 173 days was noted. Serious events including leukoencephalopathy and seizures, as well as fatal and serious cases of cerebral edema have occurred. Following YESCARTA infusion, monitor patients for signs and symptoms of neurologic toxicities at least daily for 7 days at the certified healthcare facility, and for 4 weeks thereafter, and treat promptly.



REMS:

Because of the risk of CRS and neurologic toxicities, YESCARTA is available only through a restricted program called the YESCARTA REMS which requires that: Healthcare facilities that dispense and administer YESCARTA must be enrolled and comply with the REMS requirements and must have on-site, immediate access to a minimum of 2 doses of tocilizumab for each patient for infusion within 2 hours after YESCARTA infusion, if needed for treatment of CRS. Certified healthcare facilities must ensure that healthcare providers who prescribe, dispense, or administer YESCARTA are trained about the management of CRS and neurologic toxicities. Further information is available at www.YESCARTAREMS.com or 1-844-454-KITE (5483).



海外永久免费软件加速器

Allergic reactions, including serious hypersensitivity reactions or anaphylaxis, may occur with the infusion of YESCARTA.



免费外国网络加速器

Severe or life-threatening infections occurred. Infections (all grades) occurred in 38% of patients. Grade ≥3 infections occurred in 23% of patients; those due to an unspecified pathogen occurred in 16% of patients, bacterial infections in 9%, and viral infections in 4%. YESCARTA should not be administered to patients with clinically significant active systemic infections. Monitor patients for signs and symptoms of infection before and after infusion and treat appropriately. Administer prophylactic anti-microbials according to local guidelines. Febrile neutropenia was observed in 36% of patients and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad spectrum antibiotics, fluids, and other supportive care as medically indicated. Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing.



PROLONGED CYTOPENIAS:

Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and YESCARTA infusion. Grade ≥3 cytopenias not resolved by Day 30 following YESCARTA infusion occurred in 28% of patients and included thrombocytopenia (18%), neutropenia (15%), and anemia (3%). Monitor blood counts after infusion.



HYPOGAMMAGLOBULINEMIA

and B-cell aplasia can occur. Hypogammaglobulinemia occurred in 15% of patients. Monitor immunoglobulin levels after treatment and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement. The safety of immunization with live viral vaccines during or following YESCARTA treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during YESCARTA treatment, and until immune recovery following treatment.



SECONDARY MALIGNANCIES

may develop. Monitor life-long for secondary malignancies. In the event that one occurs, contact Kite at 1-844-454-KITE (5483) to obtain instructions on patient samples to collect for testing.



免费海外网站加速器下载

里斯本欲借力国际网络峰会打造“欧洲硅谷”:通过提供办公场所与免费法律咨询推动创业的非赢利机构Beta-i公司创始人Marvao认为,当有十几个创业者几个月之 内就能募集到 5到10万欧元时,投资者就会对这里感兴趣,而有了网络峰会,里斯本就要热起来了。 值得注意的是,许多葡萄牙新企业由外国人



ADVERSE REACTIONS:

The most common (incidence ≥20%) include CRS, fever, hypotension, encephalopathy, tachycardia, fatigue, headache, decreased appetite, chills, diarrhea, febrile neutropenia, infections-pathogen unspecified, nausea, hypoxia, tremor, cough, vomiting, dizziness, constipation, and cardiac arrhythmias.



Please see full Prescribing Information, including BOXED WARNING and Medication Guide.



Indication



YESCARTA is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Limitation of Use: YESCARTA is not indicated for the treatment of patients with primary central nervous system lymphoma.

ysscloud加速器官网

  • 携手外国专家推进企业发展-国际在线:2021-2-3 · 彼得·贝内特博士 “超快激光的运用和印刷制版的改良都是行业创举,也是我伔企业引进外国专家的最大成果。”近日,第十六届中国国际人才交流大会上,由武汉市外国专家局推荐的武汉金顿激光科技有限公司(下称“金顿激光”)英国专家彼得·贝内特入选“改革开放40周年最具影响力的外国专家 ...
  • Neurologic toxicities, including life-threatening reactions, occurred in patients receiving TECARTUS, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with TECARTUS. Provide supportive care and/or corticosteroids as needed.
  • TECARTUS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the YESCARTA and TECARTUS REMS Program.

Cytokine Release Syndrome (CRS),

including life-threatening reactions, occurred following treatment with TECARTUS. In ZUMA-2, CRS occurred in 91% (75/82) of patients receiving TECARTUS, including ≥ Grade 3 CRS in 18% of patients. Among the patients who died after receiving TECARTUS, one had a fatal CRS event. The median time to onset of CRS was three days (range: 1 to 13 days) and the median duration of CRS was ten days (range: 1 to 50 days). Among patients with CRS, key manifestations (>10%) included fever (99%), hypotension (60%), hypoxia (37%), chills (33%), tachycardia (37%), headache (24%), fatigue (19%), nausea (13%), alanine aminotransferase increased (13%), aspartate aminotransferase increased (12%), and diarrhea (11%). Serious events associated with CRS included hypotension, fever, hypoxia, acute kidney injury, and tachycardia.



Ensure that a minimum of two doses of tocilizumab are available for each patient prior to infusion of TECARTUS. Following infusion, monitor patients for signs and symptoms of CRS daily for at least seven days at the certified healthcare facility, and for four weeks thereafter. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time. At the first sign of CRS, institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids as indicated.



免费外国网络加速器

including those that were life-threatening, occurred following treatment with TECARTUS. In ZUMA-2, neurologic events occurred in 81% of patients, 37% of whom experienced Grade ≥3 adverse reactions. The median time to onset for neurologic events was six days (range: 1 to 32 days). Neurologic events resolved for 52 out of 66 (79%) patients with a median duration of 21 days (range: 2 to 454 days). Three patients had ongoing neurologic events at the time of death, including one patient with serious encephalopathy. The remaining unresolved neurologic events were either Grade 1 or Grade 2. Fifty-four (66%) patients experienced CRS by the onset of neurological events. Five (6%) patients did not experience CRS with neurologic events and eight patients (10%) developed neurological events after the resolution of CRS. 85% of all treated patients experienced the first CRS or neurological event within the first seven days after TECARTUS infusion.



The most common neurologic events (>10%) included encephalopathy (51%), headache (35%), tremor (38%), aphasia (23%), and delirium (16%). Serious events including encephalopathy, aphasia, and seizures occurred.



绝地求生为什么会凉的这么快?_游戏_北方热点:2021-4-21 · 绝地求生这款游戏当时真的是火的一塌糊涂,在他还没出之前,同学放学后的对话都是:网吧CF,网吧联盟,而他出了之后大家的对话都变成了,网吧吃鸡。甚至他的地位明显威胁到了大哥英雄联盟,不仅贫民玩家流失很多



能上google免费加速器

非法经营网络翻墙软件获利 兄弟俩领刑受罚-中国法院网:2021-4-4 · 2021年2月,曾某恒在一个网络游戏群里看到有人在招VPN网络加速器的销售伕理。 在了解到VPN网络加速器具有观看国内外网站、连接国外服务器、隐藏更改IP地址等功能后,曾某恒顿时就对此产生了浓厚的兴趣,于是便主动与对方接触,最终成为了VPN网络加速器的销售伕理。



  • 真的有外星人吗?斯诺登曾去美国政府情报网求证,结论:没有:2021-10-24 · 【环球网报道 见习记者 朱海逸】世界上真的有外星人吗?美国中央情报局(CIA)和国家安全局(NSA)前雇员爱德华•斯诺登显然对此也很有兴趣。据美国 ...
  • Certified healthcare facilities must ensure that healthcare providers who prescribe, dispense, or administer TECARTUS are trained in the management of CRS and neurologic toxicities. Further information is available at www.YescartaTecartusREMS.com or 1-844-454-KITE (5483).

免费海外网站加速器下载

Serious hypersensitivity reactions, including anaphylaxis, may occur due to dimethyl sulfoxide (DMSO) or residual gentamicin in TECARTUS.



Severe Infections:

Severe or life-threatening infections occurred in patients after TECARTUS infusion. In ZUMA-2, infections (all grades) occurred in 56% of patients. Grade 3 or higher infections, including bacterial, viral, and fungal infections, occurred in 30% of patients. TECARTUS should not be administered to patients with clinically significant active systemic infections. Monitor patients for signs and symptoms of infection before and after infusion and treat appropriately. Administer prophylactic antimicrobials according to local guidelines.



Febrile neutropenia was observed in 6% of patients after TECARTUS infusion and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive care as medically indicated.



Viral Reactivation
Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing.



Prolonged Cytopenias:

Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and TECARTUS infusion. In ZUMA-2, Grade ≥3 cytopenias not resolved by Day 30 following TECARTUS infusion occurred in 55% of patients and included thrombocytopenia (38%), neutropenia (37%), and anemia (17%). Monitor blood counts after infusion.



Hypogammaglobulinemia

and B-cell aplasia can occur in patients receiving treatment with TECARTUS. In ZUMA-2, hypogammaglobulinemia occurred in 16% of patients. Monitor immunoglobulin levels after treatment with TECARTUS and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement. The safety of immunization with live viral vaccines during or following TECARTUS treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least six weeks prior to the start of lymphodepleting chemotherapy, during treatment, and until immune recovery following treatment with TECARTUS.



海外永久免费软件加速器

may develop. Monitor life-long for secondary malignancies. In the event that it occurs, contact Kite at 1-844-454-KITE (5483) to obtain instructions on patient samples to collect for testing.



能上google免费加速器

5G商用在即,车联网有望最快成为商用场景 - huanqiu.com:2021-4-16 · 美国是世界上第二个开通5G通用网络的国家,而作为美国的品牌,菲斯克将率先受益于5G网络,加速Fisker Orbit项目的开发。 与此同时,汉鼎宇佑集团控股的汉鼎宇佑(300300),其智慧城市项目遍及各地,将配合5G技术对项目所涉及的区域进行适当的数字化升级,便于车联网在线下场景中的流畅运行。



Adverse Reactions:

The most common adverse reactions (incidence ≥ 20%) were pyrexia, CRS, hypotension, encephalopathy, fatigue, tachycardia, arrhythmia, infection – pathogen unspecified, chills, hypoxia, cough, tremor, musculoskeletal pain, headache, nausea, edema, motor dysfunction, constipation, diarrhea, decreased appetite, dyspnea, rash, insomnia, pleural effusion, and aphasia. Serious adverse reactions occurred in 66% of patients. The most common serious adverse reactions (> 2%) were encephalopathy, pyrexia, infection – pathogen unspecified, CRS, hypoxia, aphasia, renal insufficiency, pleural effusion, respiratory failure, bacterial infections, dyspnea, fatigue, arrhythmia, tachycardia, and viral infections.



Please see full Prescribing Information, including 美国网络加速器免费版 and Medication Guide.



INDICATION



TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).



This indication is approved under accelerated approval based on overall response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

ysscloud加速器官网

ysscloud加速器官网

  • Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving YESCARTA®. Do not administer YESCARTA to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.
  • Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving YESCARTA, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with YESCARTA. Provide supportive care and/or corticosteroids as needed.
  • YESCARTA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the YESCARTA REMS.

CYTOKINE RELEASE SYNDROME

(CRS) occurred in 94% of patients, with 13% ≥ Grade 3. Among patients who died after receiving YESCARTA, 4 had ongoing CRS at death. The median time to onset was 2 days (range: 1-12 days) and median duration was 7 days (range: 2-58 days). Key manifestations include fever (78%), hypotension (41%), tachycardia (28%), hypoxia (22%), and chills (20%). Serious events that may be associated with CRS include cardiac arrhythmias (including atrial fibrillation and ventricular tachycardia), cardiac arrest, cardiac failure, renal insufficiency, capillary leak syndrome, hypotension, hypoxia, and hemophagocytic lymphohistiocytosis/macrophage activation syndrome. Ensure that 2 doses of tocilizumab are available prior to YESCARTA infusion. Following infusion, monitor patients for signs and symptoms of CRS at least daily for 7 days at the certified healthcare facility, and for 4 weeks thereafter. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time. At the first sign of CRS, institute treatment with supportive care, tocilizumab or tocilizumab and corticosteroids as indicated.



NEUROLOGIC TOXICITIES

occurred in 87% of patients, 98% of which occurred within the first 8 weeks with a median time to onset of 4 days (range: 1-43 days) and a median duration of 17 days. Grade ≥3 occurred in 31% of patients. The most common neurologic toxicities included encephalopathy (57%), headache (44%), tremor (31%), dizziness (21%), aphasia (18%), delirium (17%), insomnia (9%), and anxiety (9%). Prolonged encephalopathy lasting up to 173 days was noted. Serious events including leukoencephalopathy and seizures, as well as fatal and serious cases of cerebral edema have occurred. Following YESCARTA infusion, monitor patients for signs and symptoms of neurologic toxicities at least daily for 7 days at the certified healthcare facility, and for 4 weeks thereafter, and treat promptly.



REMS:

Because of the risk of CRS and neurologic toxicities, YESCARTA is available only through a restricted program called the YESCARTA REMS which requires that: Healthcare facilities that dispense and administer YESCARTA must be enrolled and comply with the REMS requirements and must have on-site, immediate access to a minimum of 2 doses of tocilizumab for each patient for infusion within 2 hours after YESCARTA infusion, if needed for treatment of CRS. Certified healthcare facilities must ensure that healthcare providers who prescribe, dispense, or administer YESCARTA are trained about the management of CRS and neurologic toxicities. Further information is available at www.YESCARTAREMS.com or 1-844-454-KITE (5483).



免费外国网络加速器

Allergic reactions, including serious hypersensitivity reactions or anaphylaxis, may occur with the infusion of YESCARTA.



SERIOUS INFECTIONS:

Severe or life-threatening infections occurred. Infections (all grades) occurred in 38% of patients. Grade ≥3 infections occurred in 23% of patients; those due to an unspecified pathogen occurred in 16% of patients, bacterial infections in 9%, and viral infections in 4%. YESCARTA should not be administered to patients with clinically significant active systemic infections. Monitor patients for signs and symptoms of infection before and after infusion and treat appropriately. Administer prophylactic anti-microbials according to local guidelines. Febrile neutropenia was observed in 36% of patients and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad spectrum antibiotics, fluids, and other supportive care as medically indicated. Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing.



PROLONGED CYTOPENIAS:

Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and YESCARTA infusion. Grade ≥3 cytopenias not resolved by Day 30 following YESCARTA infusion occurred in 28% of patients and included thrombocytopenia (18%), neutropenia (15%), and anemia (3%). Monitor blood counts after infusion.



HYPOGAMMAGLOBULINEMIA

腾讯网游加速器尽享极速网络 “吃鸡”更流畅 -新闻频道-华龙网:2021-1-19 · 原标题:腾讯网游加速器尽享极速网络 “吃鸡”更流畅 2021年开年大吉,爱好“吃鸡”玩家终于等到了《绝地求生》国服上线的消息,《绝地求生 ...



SECONDARY MALIGNANCIES

may develop. Monitor life-long for secondary malignancies. In the event that one occurs, contact Kite at 1-844-454-KITE (5483) to obtain instructions on patient samples to collect for testing.



EFFECTS ON ABILITY TO DRIVE AND USE MACHINES:

Due to the potential for neurologic events, including altered mental status or seizures, patients are at risk for altered or decreased consciousness or coordination in the 8 weeks following YESCARTA infusion. Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, during this initial period.



ADVERSE REACTIONS:

全球制药:正在强力介入互联网医疗 - huanqiu.com:2021-4-29 · 2021年6月,辛辛那提互联网医疗加速器Innov8 宣布与Sanofi和其他战略合作伙伴共同推出新的加速器。 Innov8医疗加速器项目扶持期3个月,交易6%股权 ...



Please see 海外永久免费软件加速器, including BOXED WARNING and Medication Guide.



Indication



YESCARTA is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Limitation of Use: YESCARTA is not indicated for the treatment of patients with primary central nervous system lymphoma.

ysscloud加速器官网

  • Cytokine Release Syndrome (CRS), including life-threatening reactions, occurred in patients receiving TECARTUS. Do not administer TECARTUS to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.
  • Neurologic toxicities, including life-threatening reactions, occurred in patients receiving TECARTUS, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with TECARTUS. Provide supportive care and/or corticosteroids as needed.
  • TECARTUS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the YESCARTA and TECARTUS REMS Program.

Cytokine Release Syndrome (CRS),

including life-threatening reactions, occurred following treatment with TECARTUS. In ZUMA-2, CRS occurred in 91% (75/82) of patients receiving TECARTUS, including ≥ Grade 3 CRS in 18% of patients. Among the patients who died after receiving TECARTUS, one had a fatal CRS event. The median time to onset of CRS was three days (range: 1 to 13 days) and the median duration of CRS was ten days (range: 1 to 50 days). Among patients with CRS, key manifestations (>10%) included fever (99%), hypotension (60%), hypoxia (37%), chills (33%), tachycardia (37%), headache (24%), fatigue (19%), nausea (13%), alanine aminotransferase increased (13%), aspartate aminotransferase increased (12%), and diarrhea (11%). Serious events associated with CRS included hypotension, fever, hypoxia, acute kidney injury, and tachycardia.



vpn被封翻墙党该何去何从?App Store连接不上如何解决?(图 ...:2021-1-29 · 据悉,8.8.8.8是谷歌免费公用DNS。网友认为进行这一修改,可众解决一些服务商的DNS解析问题。此前,也有消息称,修改后,可加速应用下载。 2021年12月初,国家互联网信息办公室主任鲁炜在赴美国考察时,曾与苹果CEO蒂姆·库克会面。



Neurologic Toxicities,

including those that were life-threatening, occurred following treatment with TECARTUS. In ZUMA-2, neurologic events occurred in 81% of patients, 37% of whom experienced Grade ≥3 adverse reactions. The median time to onset for neurologic events was six days (range: 1 to 32 days). Neurologic events resolved for 52 out of 66 (79%) patients with a median duration of 21 days (range: 2 to 454 days). Three patients had ongoing neurologic events at the time of death, including one patient with serious encephalopathy. The remaining unresolved neurologic events were either Grade 1 or Grade 2. Fifty-four (66%) patients experienced CRS by the onset of neurological events. Five (6%) patients did not experience CRS with neurologic events and eight patients (10%) developed neurological events after the resolution of CRS. 85% of all treated patients experienced the first CRS or neurological event within the first seven days after TECARTUS infusion.



The most common neurologic events (>10%) included encephalopathy (51%), headache (35%), tremor (38%), aphasia (23%), and delirium (16%). Serious events including encephalopathy, aphasia, and seizures occurred.



携手外国专家推进企业发展-国际在线:2021-2-3 · 彼得·贝内特博士 “超快激光的运用和印刷制版的改良都是行业创举,也是我伔企业引进外国专家的最大成果。”近日,第十六届中国国际人才交流大会上,由武汉市外国专家局推荐的武汉金顿激光科技有限公司(下称“金顿激光”)英国专家彼得·贝内特入选“改革开放40周年最具影响力的外国专家 ...



REMS Program:

Because of the risk of CRS and neurologic toxicities, TECARTUS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the YESCARTA and TECARTUS REMS Program which requires that:



  • Healthcare facilities that dispense and administer TECARTUS must be enrolled and comply with the REMS requirements. Certified healthcare facilities must have on-site, immediate access to tocilizumab, and ensure that a minimum of two doses of tocilizumab are available for each patient for infusion within two hours after TECARTUS infusion, if needed for treatment of CRS.
  • Certified healthcare facilities must ensure that healthcare providers who prescribe, dispense, or administer TECARTUS are trained in the management of CRS and neurologic toxicities. Further information is available at www.YescartaTecartusREMS.com or 1-844-454-KITE (5483).

Hypersensitivity Reactions:

Serious hypersensitivity reactions, including anaphylaxis, may occur due to dimethyl sulfoxide (DMSO) or residual gentamicin in TECARTUS.



Severe Infections:

江苏一网吧为吸引学生上网 安装翻墙软件被查处__中国青年网:2021-12-9 · 嫌生意清淡,淮安盱眙的一家网吧老板打起了周边学校学生的注意,为了招揽学生上网消费,他在电脑上安装了一款翻墙软件:可众让学生不刷身份 ...



云购物、云问诊、云办公 互联网守护美好生活_中国青年 ...:2021-3-13 · “抗疫”的非常时期人伔的日常消费习惯发生改变,为减少出门,线上购物需求激增,生鲜配送、线上购物、在线教育、远程办公、在线医疗等新型“宅经济”增长迅速。互联网创新层出不穷正深刻地改变着生活和产业生态。



Viral Reactivation
Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing.



免费外国网络加速器

Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and TECARTUS infusion. In ZUMA-2, Grade ≥3 cytopenias not resolved by Day 30 following TECARTUS infusion occurred in 55% of patients and included thrombocytopenia (38%), neutropenia (37%), and anemia (17%). Monitor blood counts after infusion.



Hypogammaglobulinemia

and B-cell aplasia can occur in patients receiving treatment with TECARTUS. In ZUMA-2, hypogammaglobulinemia occurred in 16% of patients. Monitor immunoglobulin levels after treatment with TECARTUS and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement. The safety of immunization with live viral vaccines during or following TECARTUS treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least six weeks prior to the start of lymphodepleting chemotherapy, during treatment, and until immune recovery following treatment with TECARTUS.



Secondary Malignancies

may develop. Monitor life-long for secondary malignancies. In the event that it occurs, contact Kite at 1-844-454-KITE (5483) to obtain instructions on patient samples to collect for testing.



Effects on Ability to Drive and Use Machines:

Due to the potential for neurologic events, including altered mental status or seizures, patients are at risk for altered or decreased consciousness or coordination in the 8 weeks following TECARTUS infusion. Advise patients to refrain from driving and engaging in hazardous activities, such as operating heavy or potentially dangerous machinery, during this period.



Adverse Reactions:

手机上这么好用的功能 你用过吗? - huanqiu.com:2021-9-30 · 十几年前,还是功能机的时伕,相信很多人都会觉得用手机拍照、听歌众及上网都是很新奇的事情。然而,现在的手机拥有了越来越多新奇有趣的 ...



Please see full Prescribing Information, including BOXED WARNING and Medication Guide.



INDICATION



【全国两会地方谈】华龙两江评:从两会“世界关注点”感悟 ...:2021-5-23 · 2021年中国“两会时间”5月21日正式开启。特殊时期召开的中国两会备受世界瞩目。从媒体的盘点来看,国际社会对中国两会的主要关注点重点集中在经济运行、全面小康、公共卫生、国际合作、对 …



This indication is approved under accelerated approval based on overall response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

ysscloud加速器官网

Large B-cell lymphoma
Mantle cell lymphoma

ysscloud加速器官网

Kite Pharma is not responsible for any information contained in any of these third party websites.

Cancel
Continue